Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use RYLAZE safely and effectively. See full prescribing information for RYLAZE. RYLAZE® (asparaginase erwinia chrysanthemi (recombinant)-rywn) injection, for intramuscular useInitial U.S. Approval: 2021
Medication labelWhy this: Advisory · dailymed-prescription
RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
- generic_name
- asparaginase erwinia chrysanthemi (recombinant)-rywn
- product_names
- asparaginase erwinia chrysanthemi (recombinant)-rywn
- ndc
- 68727-900, 68727-900-01, 68727-900-03
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en